Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review.
10.7534/j.issn.1009-2137.2017.02.055
- VernacularTitle:骨髓瘤耐药相关机制及联合HDACi治疗多发性骨髓瘤
- Author:
Liu-Fang GU
1
;
Xiao-Guang CUI
1
;
Xing-Mei CAO
2
,
3
;
She-Ping CHEN
1
Author Information
1. Department of Clinical Hematology, The Sencond Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.
2. Department of Clinical Hematology, The Sencond Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China. E-mail: 13892862529@
3. com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2017;25(2):608-612
- CountryChina
- Language:Chinese
-
Abstract:
Drug resistance of multiple myeloma(MM) has become more and more common, and greatly decreased the survival rate of these patients. The occurence of drug-resistance involves in many factors such as bone marrow microenveronment, tumor cell self-metabolism, cytokines, specific targets and so on. In this review, the potential mechanisms of resistance to glucocorticoid/proteasome inhibitor/immunomodulatory druges are briefly expounded in the aspect of tumor cell self-metabolism, including the changes of heat slock protein expression, mRNA expression, related cytokine levels and down-regulation of thalidomid-effecting site CRBN expression. In this review, the researches on the effect of histone deacetylase inhibitors(HDACi) combined with glucocorticoid, proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies on multiple myeloma, specially, drug-resistant multiple myeloma are also summarized.
